Background/Aims: Youth with type 2 diabetes (T2D) have poor compliance with medical care. This study aimed to determine which demographic and clinical factors differ between youth with T2D who receive care in a pediatric diabetes center versus youth lost to follow-up for >18 months. Methods: Data were analyzed from 496 subjects in the Pe-diatric Diabetes Consortium registry. Enrollment variables were selected a priori and analyzed with univariable and multivariable logistic regression models. Results: After a median of 1.3 years from enrollment, 55% of patients were lost to follow-up. The final model included age, race/ethnicity, parent education, and estimated distance to study site. The odds ratio (99% confidence interval) of loss to follow-up was 2.87 (1.34, 6.16) for those aged 15 to <18 years versus those aged 10 to <13 years and 6.57 (2.67, 16.15) for those aged ≥18 years versus those aged 10 to <13 years. Among patients living more than 50 miles from the clinic, the odds ra tio of loss to follow-up was 3.11 (1.14, 8.49) versus those living within 5 miles of the site. Conclusion: Older adolescents with T2D are more likely to be lost to follow-up, but other socioeconomic factors were not significant predictors of clinic follow-up.

Keywords:
Type 2 diabetes mellitus, Loss to follow-up, Pediatrics, Endocrinology, Obesity
1.
Centers for Disease Control Prevention: National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, US Department of Health and Human Services, 2014.
2.
Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badaru A, Talton JW, Crume T, Liese AD, Merchant AT, Lawrence JM, Reynolds K, Dolan L, Liu LL, Hamman RF: Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014;311: 1778–1786.
3.
Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, Twigg SM, Yue DK, Wong J: Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013;36: 3863–3869.
4.
Al-Saeed AH, Constantino MI, Molyneaux L, D’Souza M, Limacher-Gisler F, Luo C, Wu T, Twigg SM, Yue DK, Wong J: An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes. Diabetes Care 2016;39: 823–829.
5.
Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA: Earlier onset of complications in youth with type 2 diabetes. Diabetes Care 2014;37: 436–443.
6.
Pinhas-Hamiel O, Zeitler P: Barriers to the treatment of adolescent type 2 diabetes – a survey of provider perceptions. Pediatr Diabetes 2003;4: 24–28.
7.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28(suppl 1):S37–S42.
8.
Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S: Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011;96: 159–167.
9.
Pettitt DJ, Talton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, Liese AD, Linder B, Mayer-Davis EJ, Pihoker C, Saydah SH, Standiford DA, Hamman RF: Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care 2014; 37: 402–408.
10.
Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F: A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366: 2247–2256.
11.
Klingensmith GJ, Tamborlane WV, Wood J, Haller MJ, Silverstein J, Cengiz E, Shanmugham S, Kollman C, Wong-Jacobson S, Beck RW, Pediatric Diabetes Consortium: Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth. J Pediatr 2013;162: 330–334.e331.
12.
Wolff K, Chambers L, Bumol S, White RO, Gregory BP, Davis D, Rothman RL: The PRIDE (Partnership to Improve Diabetes Education) toolkit: development and evaluation of novel literacy and culturally sensitive diabetes education materials. Diabetes Educ 2016;42: 23–33.
13.
Auslander WF, Sterzing PR, Zayas LE, White NH: Psychosocial resources and barriers to self-management in African American adolescents with type 2 diabetes: a qualitative analysis. Diabetes Educ 2010;36: 613–622.
14.
Barlow SE, Ohlemeyer CL: Parent reasons for nonreturn to a pediatric weight management program. Clin Pediatr (Phila) 2006;45: 355–360.
15.
Hampl SE, Borner KB, Dean KM, Papa AE, Cordts KP, Smith TR, Wade KR, Davis AM: Patient attendance and outcomes in a structured weight management program. J Pediatr 2016;176: 30–35.
16.
Andemariam B, Owarish-Gross J, Grady J, Boruchov D, Thrall RS, Hagstrom JN: Identification of risk factors for an unsuccessful transition from pediatric to adult sickle cell disease care. Pediatr Blood Cancer 2014;61: 697–701.
17.
Kelly C, Hulme C, Farragher T, Clarke G: Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review. BMJ Open 2016; 6:e013059.
18.
Su D, Zhou J, Kelley MS, Michaud TL, Siahpush M, Kim J, Wilson F, Stimpson JP, Pagan JA: Does telemedicine improve treatment outcomes for diabetes? A meta-analysis of results from 55 randomized controlled trials. Diabetes Res Clin Pract 2016;116: 136–148.
19.
Carter EL, Nunlee-Bland G, Callender C: A patient-centric, provider-assisted diabetes telehealth self-management intervention for urban minorities. Perspect Health Inf Manag 2011;8: 1b.
20.
Davis RM, Hitch AD, Salaam MM, Herman WH, Zimmer-Galler IE, Mayer-Davis EJ: TeleHealth improves diabetes self-management in an underserved community: diabetes TeleCare. Diabetes Care 2010;33: 1712–1717.
21.
Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL: Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control. Diabetes Care 2011; 34: 1934–1942.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.